Please login to the form below

Not currently logged in
Email:
Password:

GSK to develop cancer drugs with OncoMed

GSK and US biotech OncoMed partner to discover, develop and market antibody therapeutics to target cancer stem cells

UK pharmaceutical company GlaxoSmithKline (GSK) and US-based biotech OncoMed Pharmaceuticals have partnered to discover, develop and market antibody therapeutics to target cancer stem cells.

Per the agreement, OncoMed could earn milestone payments of up to USD 1.4bn, based on the achievement of specified discovery, development, regulatory and commercial milestones. The biotech will also receive double-digit royalties on all collaboration product sales.

GSK has secured the option to invest in a future initial public offering (IPO) by OncoMed, which focuses on discovery and development of cancer stem cell antibody therapeutics. The move could signal a future acquisition, depending on the success of the collaboration.

GSK also has option to license four OncoMed product candidates directed at multiple cancer stem cell targets.

11th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics